Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Khalid Shah
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
AMASA Technologies
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Shah is a co-founder of AMASA Technologies, which focuses on testing stem cell based therapies in cancer patients, and he owns private equity in the company. AMASA Technologies has licensed patents that protect the stem cells loaded oncolytic virus technology (MSC-oHSV-TRIAL technology), of which Dr. Shah is named as an inventor.
The grant listed above proposes to test the therapeutic efficacy and fate of MSC/ICOVIR17, a stem cells loaded oncolytic virotherapy, in patient-derived glioblastoma xenograph models, and in immunocompetent glioblastoma models. MSC/ICOVIR17 is a genetically engineered Mesenchymal Stem Cells system loaded with an oncolytic adenovirus expressing hyaluronidase (ICOVIR17), an enzyme that degrades a molecule (Hyaluronic acid) in the brain extracellular matrix that presents a barrier to oncolytic virus delivery.
The Partners Committee on Outside Activities (COA) Financial Interest Review Panel evaluated Dr. Shah’s financial interest in AMASA Technologies in connection with this grant. The Committee determined that a research project that aims to improve oncolytic virus intra-tumoral spread and the efficacy of glioblastoma treatment was relevant to AMASA Technologies’ testing and therapeutic development efforts. The committee further determined that since the company was still in the early stage of formation, research results under this grant could affect the company’s business orientation and research direction. The Committee concluded that the financial interest was related to the research, and given its nature and magnitude, the financial interest could directly and significantly affect the design, conduct, or reporting of this research project. Therefore, the financial interest creates a conflict of interest with this grant under the PHS regulations. The Committee further determined that the conflict of interest can be managed with the implementation of management measures.
Novel oncolytic virotherapy for brain tumors
Oncolytic virus (OV) holds promise as a therapeutic modality for malignant brain tumor glioblastoma, but delivery of the virus requires improvement. We will use stem cells to deliver a tumor microenvironment modifying OV in clinically relevant glioblastoma models to develop novel approaches that have a translational potential.
Filed on August 07, 2017.
Tell us what you know about Khalid Shah's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Khalid Shah”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Khalid Shah | Brigham and Women's Hospital | Conflict of Interest | AMASA Technologies | Value cannot be readily determined |
| Khalid Shah | Brigham and Women's Hospital | Conflict of Interest | AMASA Technologies | Value cannot be readily determined |
| Khalid Shah | Brigham and Women's Hospital | Conflict of Interest | AMASA Technologies | Value cannot be readily determined |
| Khalid Shah | Brigham and Women's Hospital | Conflict of Interest | AMASA Technologies | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.